Karyopharm Therapeutics (KPTI) PT Lowered to $7 at Piper Sandler
July 31, 2026 8:35 AM
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $7.00 (from $16.00) while maintaining a Overweight rating.
